rF-PSA + rV-PSA vaccine

The rF-PSA + rV-PSA vaccine is an investigational heterologous prime-boost immunotherapy regimen evaluated by the Eastern Cooperative Oncology Group (ECOG) for the treatment of prostate cancer. The vaccine system utilizes two distinct recombinant poxviral vectors: a vaccinia virus (rV-PSA) and a fowlpox virus (rF-PSA), both engineered to express human prostate-specific antigen (PSA). This strategy is designed to overcome the anti-vector immunity that often limits the efficacy of repeated doses of the same viral vector. By alternating the vectors, the vaccine more effectively primes and boosts a T-cell-mediated immune response specifically targeting PSA-expressing malignant cells. This early iteration of the vaccine, tested in Phase II trials like E7897, served as the precursor to the later-developed PROSTVAC (PROSTVAC-TRICOM), which incorporated additional costimulatory molecules (B7-1, ICAM-1, and LFA-3) to further enhance the immune response.

Other names

recombinant fowlpox-prostate-specific antigen vaccinerecombinant vaccinia-prostate-specific antigen vaccinePSA vaccinerF-PSA/rV-PSArecombinant fowlpox-prostate-specific antigen vaccine-Eastern Cooperative Oncology Group-prostate cancer